Digital upgrading has become the endogenous demand of pharmaceutical companies, and the pace of innovation and upgrading of upstream pharmaceutical equipment will also accelerate

According to a new analysis of Yuanyi Capital's global digital health database, digital medical startups account for nearly 50% of all medical startups that have received financing in more than 65,000 medical projects in the United States in the past 20 years; Looking at the more than 42,000 medical projects in China in the past 20 years, digital medical startups account for less than 10% of all medical startups that have received financing, which shows that China still has a lot of room
for development.
In recent years, with the aging of the population, the advancement of new medical reform, and the release of favorable policies, more and more biomedical companies have begun to embrace digital transformation, and it is expected that the domestic digital medical field will have great development opportunities
。 Digital upgrading into the endogenous demand of pharmaceutical enterprises, the pace of upstream pharmaceutical equipment innovation and upgrading will also accelerate (Image source: Pharmaceutical Network) Digital upgrade into endogenous demand of pharmaceutical enterprises At present, under the background of the rapid development of new technologies such as 5G, big data, and edge computing, the transformation of traditional manufacturing is accelerating, and in the field of biomedicine, as the labor cost of pharmaceutical companies rises year by year, centralized procurement and price reduction become a trend, digital upgrading has also become the endogenous demand of pharmaceutical companies, covering R&D, production, marketing, supply, procurement, service and other links
。 It is reported that Ma Yinglong Company is accelerating intelligent upgrades, and has reached 100% intelligence of production lines and 100% networked equipment; Through the application of 5G+ digital twin, the company has also built a value warehouse covering the whole site, obtained data in real time, realized timely and transparent management of the production process, increased the capacity efficiency to 26.
6%, reduced the defective rate by 19%, reduced the capacity energy consumption by 10.
5%, and reduced the operating cost by 21%.

。 Yunnan Baiyao has also accelerated its digital transformation in recent years, such as the "Digital Sanqi Industry Platform" it has built, integrating R&D and planting, production and processing, warehousing and logistics, quality traceability, sales and service, realizing the data control and monitoring of the whole industry link and the whole cycle, injecting new vitality
into the traditional Chinese medicine industry.
Pacific's newly released research report pointed out that the application of digital factories in the pharmaceutical field is currently in a rapid promotion stage, according to Statista, in 2017, the application rate of digital factories in the field of life sciences and biopharmaceuticals was 37%, significantly lower than other industries
。 According to ABIResearch's 2021 research report, the pharmaceutical industry will invest US$4.
5 billion in digital factories in 2030, of which the expenditure on data analysis will reach US$1.
2 billion by 2030, with a CAGR of 27%.

The pace of innovation and upgrading of upstream pharmaceutical equipment will also accelerate With the expansion of pharmaceutical companies' demand for digital upgrading, the upstream pharmaceutical equipment industry has both opportunities and challenges, and it is expected that the pace of innovation and upgrading in the industry will further accelerate
in the future.
The policy supports the development
of pharmaceutical equipment in the direction of automation, digitalization and intelligence.
The "14th Five-Year Plan for the Development of Bioeconomy" released in May this year emphasizes promoting the development of the bioinformatics industry, using information technology to support the development of new drugs, and improving the automation, digitalization and intelligence of
pharmaceutical equipment.
Not long ago, Shanghai also issued the Implementation Opinions on Comprehensively Strengthening the Capacity Building of Drug Supervision, proposing to promote the deep integration of a new generation of information technology and the biomedical industry, accelerate artificial intelligence-empowered innovation and research and development, improve the level of intelligent automated production of the industrial chain, promote the digital development of technical service models, and accelerate the construction of
digital demonstration enterprises.
At present, many pharmaceutical equipment companies have actively embraced digital transformation to help biomedical R&D and production
.
In November this year, at the second "Shanghai International Biomedical Industry Week", Dongfulong Technology and seven other enterprises obtained the certificate of digital transformation pioneer enterprise in
the biomedical industry.
It is reported that the vision of Dongfulong is to first turn Dongfulong into a smart pharmaceutical equipment factory through internal digital construction, and then provide customers with products and services through external digital construction, build smart pharmaceutical factories for customers, and realize Dongfulong's corporate vision
of becoming a smart pharmaceutical factory deliverer.
Coincidentally, Chutian Technology is also actively exploring digital and intelligent manufacturing models
.
In October this year, Chutian Science and Technology Polymer Material Industrial Park started construction in Ningxiang Economic Development Zone, which means that Chutian Life Science Industrial City ushered in the eighth landing project
.
It is reported that the planning and planning of Chutian Life Science Industrial City specifically targets the key core technologies and high-precision technologies in the field of biomedicine, and focuses on the localization of core components in the field of pharmaceutical equipment to achieve intelligence and digitalization, and accelerate the strengthening of the chain
.
It is worth mentioning that the current biomedical industry is a special industry related to human health and safety, the current industry is not mature enough digitalization, the country is still in its infancy, pharmaceutical companies in the process of exploration still have challenges in safety, compliance and other aspects, so it needs to be gradual
.
As the upstream of the biomedical industry, pharmaceutical equipment companies need to have the courage to grasp the pain points of pharmaceutical companies, constantly make breakthroughs, and assist the digital transformation and upgrading of the pharmaceutical industry to accelerate
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.